July 31, 2015
AbbVie announced second quarter financial results and showed Viekira Pak global sales were nearly $400 million, which assisted the company in reaching an overall global sales total of $5 billion, according to a press release from AbbVie.
According to the financial report, global sales were $5.475 billion for the second quarter, which is an 11% increase from the second quarter of 2014. The release states that the total company sales growth was “driven” by Viekira Pak (ombitasvir/paritaprevir/ritonavir plus dasabuvir, AbbVie) sales, which are currently approved for the treatment of HCV in 47 countries. In the U.S., Viekira Pak earned $227 million in sales and $158 million internationally.